Universidad Complutense de Madrid
E-Prints Complutense

Current Perspectives on the Use of Anti-VEGF Drugs as Adjuvant Therapy in Glaucoma

Impacto

Descargas

Último año

Andrés Guerrero, Vanessa y Perucho González, Lucía y García Feijoo, Julián y Morales Fernández, Laura y Sáenz Francés, Federico y Herrero Vanrell, Mª Rocío y Pablo Júlvez, Luis y Polo Llorens, Vicente y Martínez de la Casa, Jose Maria y Konstas, Anastasios Georgios P. (2017) Current Perspectives on the Use of Anti-VEGF Drugs as Adjuvant Therapy in Glaucoma. Advances in Therapy, 34 (2). pp. 378-395. ISSN 0741-238X

[img]
Vista previa
PDF
Creative Commons License
Esta obra está bajo una licencia de Creative Commons: Reconocimiento - No comercial.

695kB

URL Oficial: https://dx.doi.org/10.1007%2Fs12325-016-0461-z




Resumen

The approval of one of the first anti-vascular endothelial growth factor (VEGF) agents for the treatment of neovascular age-related macular degeneration one decade ago marked the beginning of a new era in the management of several sight-threatening retinal diseases. Since then, emerging evidence has demonstrated the utility of these therapies for the treatment of other ocular conditions characterized by elevated VEGF levels. In this article we review current perspectives on the use of anti-VEGF drugs as adjuvant therapy in the management of neovascular glaucoma (NVG). The use of anti-VEGFs for modifying wound healing in glaucoma filtration surgery (GFS) is also reviewed. Selected studies investigating the use of anti-VEGF agents or antimetabolites in GFS or the management of NVG have demonstrated that these agents can improve surgical outcomes. However, anti-VEGF agents have yet to demonstrate specific advantages over the more established agents commonly used today. Further studies are needed to evaluate the duration of action, dosing intervals, and toxicity profile of these treatments.


Tipo de documento:Artículo
Información Adicional:

Received: October 17, 2016 / Published online: December 20, 2016.
To view enhanced content for this article go to: http://www.medengine.com/Redeem/4237F06040074294.

Palabras clave:Angiogénesis ; Aflibercept ; Bevacizumab ; Glaucoma filtration surgery ; Neovascular glaucoma ; Ranibizumab, VEGF, Wound modulation
Materias:Ciencias Biomédicas > Medicina > Oftalmología
Ciencias Biomédicas > Farmacia > Medicamentos
Código ID:44600
Depositado:14 Sep 2017 12:48
Última Modificación:14 Sep 2017 12:48

Descargas en el último año

Sólo personal del repositorio: página de control del artículo